The End of ACE Inhibitors? - Frankly Speaking EP 253Guest: Robert A. Baldor, MD, FAAFP
Music Credit: Richard Onorato

ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers) are both recommended as first-line treatments for hypertension. ACE inhibitors have known side effects, such as cough, that are frustrating for many patients, while ARBs appear to have less annoying side effects. This podcast will review a recently published retrospective, comparative cohort study comparing the effectiveness and safety of ACE inhibitors vs ARBs in the first-line treatment of hypertension.

Episode References and Resources:

Hypertension. 2021;78:591–603. DOI: 10.1161/HYPERTENSIONAHA.120.16667
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–e248. doi: 10.1016/j.jacc.2017.11.006

Begin

Already listened on another platform?

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 12/6/2021

Expiration Date: 12/6/2022

Topics

Learning Objectives

Apply the latest data regarding the efficacy and indications for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the treatment of hypertension
Appreciate the risks and side effects of ACE inhibitors vs ARBs
Consider prescribing ARBs as first-line treatment for hypertension

Faculty

Frank J. Domino, MD

Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Learn More

Robert A. Baldor, MD, FAAFP

Professor and Chairman, Dept of Family Medicine
UMass Medical School/Baystate

Learn More

Supported by

Not Applicable

Education Partner

Not Applicable